The yin and yang of evasion and immune activation in HCC

Journal of Hepatology

Volumn 62, Issue 6, 2015, Pages 1420-1429

  Makarova Rusher, Oxana V ^a   Medina Echeverz, José ^a   Duffy, Austin G ^a   Greten, Tim F ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Hepatocellular carcinoma; Immune checkpoints; Immunotherapy

Indexed keywords

CANCER VACCINE; CYTOKINE;

ADOPTIVE IMMUNOTHERAPY; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL TRANSFER; CHINESE MEDICINE; CHRONIC INFLAMMATION; HUMAN; IMMUNE DEFICIENCY; IMMUNE EVASION; IMMUNOLOGICAL TOLERANCE; LIVER CELL CARCINOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH; TUMOR IMMUNITY; ADOPTIVE TRANSFER; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LIVER NEOPLASMS; PROCEDURES;

ADOPTIVE TRANSFER; CANCER VACCINES; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS AS TOPIC; CYTOKINES; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; IMMUNOTHERAPY; LIVER NEOPLASMS;

EID: 84929606478     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2015.02.038     Document Type: Review

References (117)

1. J. Ferlay, I. Soerjomataram, and R. Dikshit Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 Int J Cancer 2014
2. A. Shlomai, Y.P. de Jong, and C.M. Rice Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma Semin Cancer Biol 26 2014 78 88
3. N.H. Park, Y.H. Chung, and H.S. Lee Impacts of vaccination on hepatitis B viral infections in Korea over a 25-year period Intervirology 53 2010 20 28
4. T.M. Welzel, B.I. Graubard, and S. Quraishi Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States Am J Gastroenterol 108 2013 1314 1321
5. S.V. Ulahannan, A.G. Duffy, and T.S. McNeel Earlier presentation and application of curative treatments in hepatocellular carcinoma Hepatology 2014
6. J.M. Llovet, S. Ricci, and V. Mazzaferro Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
7. A.I. Jacob, P.K. Goldberg, N. Bloom, G.A. Degenshein, and P.J. Kozinn Endotoxin and bacteria in portal blood Gastroenterology 72 1977 1268 1270
8. I.N. Crispe Hepatic T cells and liver tolerance Nat Rev Immunol 3 2003 51 62
9. V. Sriwatanawongsa, H.S. Davies, and R.Y. Calne The essential roles of parenchymal tissues and passenger leukocytes in the tolerance induced by liver grafting in rats Nat Med 1 1995 428 432
10. P. Knolle, J. Schlaak, A. Uhrig, P. Kempf, K.H. Meyer zum Buschenfelde, and G. Gerken Human Kupffer cells secrete IL-10 in response to lipopolysaccharide (LPS) challenge J Hepatol 22 1995 226 229
11. P.A. Knolle, T. Germann, and U. Treichel Endotoxin down-regulates T cell activation by antigen-presenting liver sinusoidal endothelial cells J Immunol 162 1999 1401 1407
12. U. Protzer, M.K. Maini, and P.A. Knolle Living in the liver: hepatic infections Nat Rev Immunol 12 2012 201 213
13. D.M. Bissell, S.S. Wang, W.R. Jarnagin, and F.J. Roll Cell-specific expression of transforming growth factor-beta in rat liver. Evidence for autocrine regulation of hepatocyte proliferation J Clin Invest 96 1995 447 455
14. J.P. Bottcher, O. Schanz, and D. Wohlleber Liver-primed memory T cells generated under noninflammatory conditions provide anti-infectious immunity Cell Rep 3 2013 779 795
15. J.P. Bottcher, O. Schanz, and C. Garbers IL-6 trans-signaling-dependent rapid development of cytotoxic CD8+ T cell function Cell Rep 8 2014 1318 1327
16. W. Li, C.S. Kuhr, and X.X. Zheng New insights into mechanisms of spontaneous liver transplant tolerance: the role of Foxp3-expressing CD25+CD4+ regulatory T cells Am J Transplant 8 2008 1639 1651
17. M. Muhlbauer, M. Fleck, and C. Schutz PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis J Hepatol 45 2006 520 528
18. M.C. Yu, C.H. Chen, and X. Liang Inhibition of T-cell responses by hepatic stellate cells via B7-H1-mediated T-cell apoptosis in mice Hepatology 40 2004 1312 1321
19. L. Diehl, A. Schurich, R. Grochtmann, S. Hegenbarth, L. Chen, and P.A. Knolle Tolerogenic maturation of liver sinusoidal endothelial cells promotes B7-homolog 1-dependent CD8+ T cell tolerance Hepatology 47 2008 296 305
20. R. Kassel, M.W. Cruise, J.C. Iezzoni, N.A. Taylor, T.L. Pruett, and Y.S. Hahn Chronically inflamed livers up-regulate expression of inhibitory B7 family members Hepatology 50 2009 1625 1637
21. X. Gu, Y. Wang, and J. Xiang Interferon- gamma triggers hepatic stellate cell-mediated immune regulation through MEK/ERK signaling pathway Clin Dev Immunol 2013 2013 389807
22. F. Calabrese, M. Valente, and C. Giacometti Parenchymal transforming growth factor beta-1: its type II receptor and Smad signaling pathway correlate with inflammation and fibrosis in chronic liver disease of viral etiology J Gastroenterol Hepatol 18 2003 1302 1308
23. A. Huang, B. Zhang, and W. Yan Myeloid-derived suppressor cells regulate immune response in patients with chronic hepatitis b virus infection through PD-1-induced IL-10 J Immunol 193 2014 5461 5469
24. D. Xu, J. Fu, and L. Jin Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B J Immunol 177 2006 739 747
25. H.H. Zhang, M.H. Mei, and R. Fei Regulatory T cells in chronic hepatitis B patients affect the immunopathogenesis of hepatocellular carcinoma by suppressing the anti-tumour immune responses J Viral Hepatitis 17 2010 34 43
26. K. Matsuzaki, M. Murata, and K. Yoshida Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma Hepatology 46 2007 48 57
27. G. Nebbia, D. Peppa, and A. Schurich Upregulation of the Tim-3/galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection PLoS One 7 2012 e47648
28. G. Peng, S. Li, W. Wu, X. Tan, Y. Chen, and Z. Chen PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients Mol Immunol 45 2008 963 970
29. N. Nakamoto, H. Cho, and A. Shaked Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade PLoS Pathog 5 2009 e1000313
30. H. Murakami, S.M. Akbar, H. Matsui, N. Horiike, and M. Onji Decreased interferon-alpha production and impaired T helper 1 polarization by dendritic cells from patients with chronic hepatitis C Clin Exp Immunol 137 2004 559 565
31. C. Bain, A. Fatmi, F. Zoulim, J.P. Zarski, C. Trepo, and G. Inchauspe Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection Gastroenterology 120 2001 512 524
32. J. Martinet, T. Dufeu-Duchesne, and J. Bruder Costa Altered functions of plasmacytoid dendritic cells and reduced cytolytic activity of natural killer cells in patients with chronic HBV infection Gastroenterology 143 2012 e8
33. R. Cabrera, Z. Tu, and Y. Xu An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection Hepatology 40 2004 1062 1071
34. B.S. Liu, Z.M. Groothuismink, H.L. Janssen, and A. Boonstra Role for IL-10 in inducing functional impairment of monocytes upon TLR4 ligation in patients with chronic HCV infections J Leukoc Biol 89 2011 981 988
35. F. Shi, M. Shi, and Z. Zeng PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients Int J Cancer 128 2011 887 896
36. N. Nakamoto, D.E. Kaplan, and J. Coleclough Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization Gastroenterology 134 2008 1927 1937 37 e1-2
37. J.P. Moorman, J.M. Wang, and Y. Zhang Tim-3 pathway controls regulatory and effector T cell balance during hepatitis C virus infection J Immunol 189 2012 755 766
38. R.D. Schreiber, L.J. Old, and M.J. Smyth Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion Science 331 2011 1565 1570
39. M. Matsui, S. Machida, T. Itani-Yohda, and T. Akatsuka Downregulation of the proteasome subunits, transporter, and antigen presentation in hepatocellular carcinoma, and their restoration by interferon-gamma J Gastroenterol Hepatol 17 2002 897 907
40. K. Kurokohchi, M. Carrington, and D.L. Mann Expression of HLA class I molecules and the transporter associated with antigen processing in hepatocellular carcinoma Hepatology 23 1996 1181 1188
41. L.A. Ormandy, T. Hillemann, H. Wedemeyer, M.P. Manns, T.F. Greten, and F. Korangy Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma Cancer Res 65 2005 2457 2464
42. E. Unitt, S.M. Rushbrook, and A. Marshall Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells Hepatology 41 2005 722 730
43. E. Cariani, M. Pilli, and A. Zerbini Immunological and molecular correlates of disease recurrence after liver resection for hepatocellular carcinoma PLoS One 7 2012 e32493
44. B. Hoechst, L.A. Ormandy, and M. Ballmaier A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells Gastroenterology 135 2008 234 243
45. X.D. Zhu, J.B. Zhang, and P.Y. Zhuang High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma J Clin Oncol 26 2008 2707 2716
46. O.W. Yeung, C. Lo, and C. Ling Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma J Hepatol 2014
47. T. Ding, J. Xu, and F. Wang High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection Hum Pathol 40 2009 381 389
48. S. Behboudi, A. Alisa, S. Boswell, J. Anastassiou, A.A. Pathan, and R. Williams Expansion of anti-AFP Th1 and Tc1 responses in hepatocellular carcinoma occur in different stages of disease Br J Cancer 102 2010 748 753
49. Q. Gao, S.J. Qiu, and J. Fan Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection J Clin Oncol 25 2007 2586 2593
50. J. Fu, D. Xu, and Z. Liu Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients Gastroenterology 132 2007 2328 2339
51. A. Budhu, M. Forgues, and Q.H. Ye Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment Cancer Cell 10 2006 99 111
52. E. Hattori, K. Okumoto, and T. Adachi Possible contribution of circulating interleukin-10 (IL-10) to anti-tumor immunity and prognosis in patients with unresectable hepatocellular carcinoma Hepatol Res 27 2003 309 314
53. K. Fujiwara, T. Higashi, and K. Nouso Decreased expression of B7 costimulatory molecules and major histocompatibility complex class-I in human hepatocellular carcinoma J Gastroenterol Hepatol 19 2004 1121 1127
54. T. Tatsumi, T. Takehara, and K. Katayama Expression of costimulatory molecules B7-1 (CD80) and B7-2 (CD86) on human hepatocellular carcinoma Hepatology 25 1997 1108 1114
55. Y. Wu, D.M. Kuang, and W.D. Pan Monocyte/macrophage-elicited natural killer cell dysfunction in hepatocellular carcinoma is mediated by CD48/2B4 interactions Hepatology 57 2013 1107 1116
56. P.N. Hsu, T.C. Yang, and J.T. Kao Increased PD-1 and decreased CD28 expression in chronic hepatitis B patients with advanced hepatocellular carcinoma Liver Int 30 2010 1379 1386
57. K. Sugimoto, K. Shiraki, and T. Ito Expression of functional CD40 in human hepatocellular carcinoma Hepatology 30 1999 920 926
58. A. Morales-Kastresana, M.F. Sanmamed, and I. Rodriguez Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model Clin Cancer Res 19 2013 6151 6162
59. K. Wu, I. Kryczek, L. Chen, W. Zou, and T.H. Welling Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions Cancer Res 69 2009 8067 8075
60. T. Okazaki, and T. Honjo The PD-1-PD-L pathway in immunological tolerance Trends Immunol 27 2006 195 201
61. D.M. Kuang, Q. Zhao, and C. Peng Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1 J Exp Med 206 2009 1327 1337
62. Y. Han, Z. Chen, and Y. Yang Human CD14+ CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma Hepatology 59 2014 567 579
63. S. Kalathil, A.A. Lugade, A. Miller, R. Iyer, and Y. Thanavala Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality Cancer Res 73 2013 2435 2444
64. E. Mizukoshi, Y. Nakamoto, and K. Arai Comparative analysis of various tumor-associated antigen-specific T-cell responses in patients with hepatocellular carcinoma Hepatology 53 2011 1206 1216
65. F.J. Li, Y. Zhang, G.X. Jin, L. Yao, and D.Q. Wu Expression of LAG-3 is coincident with the impaired effector function of HBV-specific CD8(+) T cell in HCC patients Immunol Lett 150 2013 116 122
66. H. Li, K. Wu, and K. Tao Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma Hepatology 56 2012 1342 1351
67. S.M. Stemmer, O. Benjaminov, and G. Medalia CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study Oncologist 18 2013 25 26
68. B.J. Wang, J.J. Bao, and J.Z. Wang Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma World J Gastroenterol 17 2011 3322 3329
69. Q. Gao, X.Y. Wang, and S.J. Qiu Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma Clin Cancer Res 15 2009 971 979
70. R. Thimme, M. Neagu, and T. Boettler Comprehensive analysis of the alpha-fetoprotein-specific CD8+ T cell responses in patients with hepatocellular carcinoma Hepatology 48 2008 1821 1833
71. L.H. Butterfield, A. Ribas, and W.S. Meng T-cell responses to HLA-Aâ - 0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer Clin Cancer Res 9 2003 5902 5908
72. G. Bricard, H. Bouzourene, and O. Martinet Naturally acquired MAGE-A10- and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma J Immunol 174 2005 1709 1716
73. A.J. Gehring, Z.Z. Ho, and A.T. Tan Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma Gastroenterology 137 2009 682 690
74. F. Korangy, L.A. Ormandy, and J.S. Bleck Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma Clin Cancer Res 10 2004 4332 4341
75. E. Mizukoshi, Y. Nakamoto, and Y. Marukawa Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma Hepatology 43 2006 1284 1294
76. K. Hiroishi, J. Eguchi, and T. Baba Strong CD8(+) T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma J Gastroenterol 45 2010 451 458
77. H. Komori, T. Nakatsura, and S. Senju Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma Clin Cancer Res 12 2006 2689 2697
78. N. van Rooij, M.M. van Buuren, and D. Philips Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma J Clin Oncol 31 2013 e439 e442
79. P.F. Robbins, Y.C. Lu, and M. El-Gamil Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells Nat Med 19 2013 747 752
80. E. Unitt, A. Marshall, and W. Gelson Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation J Hepatol 45 2006 246 253
81. E. Cariani, M. Pilli, and A. Zerbini HLA and killer immunoglobulin-like receptor genes as outcome predictors of hepatitis C virus-related hepatocellular carcinoma Clin Cancer Res 19 2013 5465 5473
82. W.C. Lee, H.C. Wang, C.F. Hung, P.F. Huang, C.R. Lia, and M.F. Chen Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial J Immunother 28 2005 496 504
83. F. Tada, M. Abe, and M. Hirooka Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma Int J Oncol 41 2012 1601 1609
84. T.F. Greten, A. Forner, and F. Korangy A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma BMC Cancer 10 2010 209
85. D.H. Palmer, R.S. Midgley, and N. Mirza A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma Hepatology 49 2009 124 132
86. L.H. Butterfield, J.S. Economou, T.C. Gamblin, and D.A. Geller Alpha fetoprotein DNA prime and adenovirus boost immunization of two hepatocellular cancer patients J Transl Med 12 2014 86
87. Y. Sawada, T. Yoshikawa, and D. Nobuoka Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival Clin Cancer Res 18 2012 3686 3696
88. T. Flecken, N. Schmidt, and S. Hild Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma Hepatology 59 2014 1415 1426
89. S. Laurent, P. Carrega, and D. Saverino CTLA-4 is expressed by human monocyte-derived dendritic cells and regulates their functions Hum Immunol 71 2010 934 941
90. R. de Waal Malefyt, J. Haanen, and H. Spits Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression J Exp Med 174 1991 915 924
91. Y. Hong, Y. Peng, and Z.S. Guo Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinoma Hepatology 59 2014 1448 1458
92. T. Takayama, T. Sekine, and M. Makuuchi Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial Lancet 356 2000 802 807
93. S.A. Rosenberg, M.T. Lotze, and L.M. Muul Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer N Engl J Med 313 1985 1485 1492
94. K. Shimizu, Y. Kotera, and A. Aruga Postoperative dendritic cell vaccine plus activated T-cell transfer improves the survival of patients with invasive hepatocellular carcinoma Hum Vaccin Immunother 10 2014 970 976
95. S. Kubo, S. Nishiguchi, and K. Hirohashi Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial Ann Intern Med 134 2001 963 967
96. J.M. Llovet, M. Sala, and L. Castells Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma Hepatology 31 2000 54 58
97. Y. Shiratori, S. Shiina, and T. Teratani Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus Ann Intern Med 138 2003 299 306
98. V. Mazzaferro, R. Romito, and M. Schiavo Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis Hepatology 44 2006 1543 1554
99. H.C. Sun, Z.Y. Tang, and L. Wang Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial J Cancer Res Clin Oncol 132 2006 458 465
100. C.M. Lo, C.L. Liu, and S.C. Chan A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma Ann Surg 245 2007 831 842
101. L.T. Chen, M.F. Chen, and L.A. Li Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection Ann Surg 255 2012 8 17
102. T. Ishikawa, K. Higuchi, and T. Kubota Combination PEG-IFN a-2b/ribavirin therapy following treatment of hepatitis C virus-associated hepatocellular carcinoma is capable of improving hepatic functional reserve and survival Hepatogastroenterology 59 2012 529 532
103. B. Sangro, G. Mazzolini, and J. Ruiz Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors J Clin Oncol 22 2004 1389 1397
104. G. Mazzolini, C. Alfaro, and B. Sangro Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas J Clin Oncol 23 2005 999 1010
105. S.J. Faivre, A. Santoro, and R.K. Kelley A phase 2 study of a novel transforming growth factor-beta (TGF-β1) receptor I kinase inhibitor, LY2157299 monohydrate (LY), in patients with advanced hepatocellular carcinoma (HCC) J Clin Oncol 32 2014 abstr LBA173
106. B. Sangro, C. Gomez-Martin, and M. de la Mata A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C J Hepatol 59 2013 81 88
107. A.G. Duffy, S.V. Ulahannan, and S. Fioravanti A pilot study of tremelimumab, a monoclonal antibody against CTLA-4, in combination with either transcatheter arterial chemoembolization (TACE) or radiofrequency ablation (RFA) in patients with hepatocellular carcinoma (HCC) J Clin Oncol 32 2014 abstr e15133
108. B. Sangro, T.S. Crocenzi, and T.H. Welling Phase I dose escalation study of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with advanced hepatocellular carcinoma (HCC) with or without chronic viral hepatitis J Clin Oncol 31 2013 abstr TPS3111
109. H. Safran, K.P. Charpentier, and A. Kaubisch Lenalidomide for second-line treatment of advanced hepatocellular cancer: a Brown University Oncology Group Phase II Study Am J Clin Oncol 2013
110. C.J. Yen, B. Daniel, and M. Kudo Randomized phase II trial of intravenous RO5137382/GC33 at 1600 mg every other week and placebo in previously treated patients with unresectable hepatocellular carcinoma (HCC; NCT01507168) J Clin Oncol 32 2014 5c, abstr 4102
111. W. Sun, D. Nelson, and S.R. Alberts Phase Ib study of mapatumumab in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) and chronic viral hepatitis J Clin Oncol 29 2011 abstr 261
112. M.N. Saleh, I. Percent, and T.E. Wood A phase I study of CS-1008 (humanized monoclonal antibody targeting death receptor 5 or DR5), administered weekly to patients with advanced solid tumors or lymphomas J Clin Oncol 2008 3537
113. M. Serova, A. Tijeras-Raballand, and C. Dos Santos Effects of TGF-beta signaling inhibition with LY2157299 in hepatocarcinoma models and in ex vivo whole tumor tissue samples from patient specimen Cancer Res. 73 2013 2094
114. E. Mizukoshi, T. Yamashita, and K. Arai Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma Hepatology 57 2013 1448 1457
115. M. Krusch, J. Salih, and M. Schlicke The kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitro J Immunol 183 2009 8286 8294
116. Y. Chen, Y. Huang, and T. Reiberger Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice Hepatology 59 2014 1435 1447
117. Y. Chen, R.R. Ramjiawan, and T. Reiberger CXCR4 inhibition in tumor microenvironment facilitates anti-PD-1 immunotherapy in sorafenib-treated HCC in mice Hepatology 2014